Weight-Loss drug for lung cancer patients put to the test

NCT ID NCT07477808

Not yet recruiting Symptom relief Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a liquid form of megestrol acetate (a drug that stimulates appetite) can help malnourished people with non-small cell lung cancer gain weight while they receive standard chemotherapy. About 116 participants will be randomly assigned to get either the drug plus standard treatment or standard treatment alone. The main goal is to see if body weight improves over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: megestrol acetate oral suspension
What this could lead to: If it works, this could provide a way to help lung cancer patients maintain or gain weight during chemotherapy, improving their strength and quality of life.
What could go wrong: This is an early-stage trial with only 116 participants, so results may not apply to everyone. The drug may cause side effects like blood clots or fluid retention, and weight gain may not improve cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.